எண்டோவாஸ்குலர் லிமிடெட் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from எண்டோவாஸ்குலர் லிமிடெட். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In எண்டோவாஸ்குலர் லிமிடெட் Today - Breaking & Trending Today

Cerus Endovascular Announces IDE Approval from the U.S. FDA to Conduct Clinical Study of the Contour Neurovascular System™

Share this article
Share this article
FREMONT, Calif. and OXFORD, United Kingdom, April 21, 2021 /PRNewswire/ Cerus Endovascular Ltd., a privately held, commercial-stage medical device company, today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device Exemption (IDE) application to conduct a U.S. trial for the Contour Neurovascular System™, indicated for the treatment of intracranial aneurysms. The IDE approval follows the receipt of Breakthrough Device Designation from the FDA in February 2021.
We are eager to move ahead with this important trial and anticipate patient enrollment beginning within the next three months, stated Dr. Stephen Griffin, President of Cerus Endovascular. The IDE study protocol closely aligns with protocols of other intra-saccular aneurysm repair devices that have received FDA approval. Given the real-world patient outcomes we have experienced in Europe, where the Contour Neurovascular Syste ....

United Kingdom , Sam Milstein , Stephen Griffin , Lori Adels , Cerus Endovascular , Prnewswire Cerus Endovascular Ltd , Cerus Endovascular Ltd , Drug Administration , Rx Communications Group , Endovascular Ltd , Investigational Device Exemption , Contour Neurovascular System , Breakthrough Device Designation , Premarket Approval , Ceru Chairman , Chief Compliance Officer , Neqstent Coil Assisted Flow Diverter , Communications Group , ஒன்றுபட்டது கிஂக்டம் , சாம் மில்ஸ்டீன் , ஸ்டீபன் கிரிஃபின் , ர்க்ஸ் தகவல்தொடர்புகள் குழு , எண்டோவாஸ்குலர் லிமிடெட் , திருப்புமுனை சாதனம் பதவி , தலைமை இணக்கம் அதிகாரி , தகவல்தொடர்புகள் குழு ,

Oxford Endovascular raises $10M to develop 'origami' medical device

Credit: OxiFlow
Origami is more traditionally associated with the art of paper folding, but one British startup is using the technique to develop a treatment for brain aneurysms.
Oxford Endovascular Ltd has raised $10 million in Series A funding for its OxiFlow solution, which aims to overcome challenges with existing medical devices.
Vulpes Investment Management led the round, with the Additio Investment Group, Oxford Sciences Innovation PLC, Parkwalk Advisors, Perivoli Innovations, Oxford Investment Consultants, the University of Oxford and private individuals following on.
The Oxford University spin-out has previously won funding from the European Union’s Horizon 2020 SME instrument and the UK’s grant programme, Innovate UK. ....

United Kingdom , Mike Karim , Alun Williams , Oxford Endovascular , Martin Diggle , Oxford Endovascular Oxiflow , Nick Dixon Clegg , European Union Horizon , Oxford Endovascular Ltd , Oxford Sciences Innovation , University Of Oxford , Additio Investment Group , Oxford University , Endovascular Ltd , Investment Management , Parkwalk Advisors , Perivoli Innovations , Oxford Investment Consultants , European Union , Innovate United , Vulpes Investment Management , Sciences Innovation , ஒன்றுபட்டது கிஂக்டம் , அழுந்த வில்லியம்ஸ் , ஆக்ஸ்ஃபர்ட் எண்டோவாஸ்குலர் , ஐரோப்பிய தொழிற்சங்கம் அடிவானம் ,

$4.16 Billion Neurovascular Intervention Devices Market - Global Forecast to 2027 - Acquisitions and Partnerships as a Part of the Growth Strategy

Share this article
Share this article
ResearchAndMarkets.com s offering.
The Neurovascular Intervention Devices global market is expected to grow at a high single digit CAGR to reach $4,167.4 million by 2027.
Over the decade, due to the technological advancements with emerging and innovative technologies used under minimally invasive conditions has led to the rapid development of neurovascular interventions. As a result of rapid advances, there is the great expansion in the potential therapeutic application for neurovascular diseases.
Neurovascular Interventional devices are used to treat intracranial aneurysm, ischemic stroke, arteriovenous malformation, carotid stenosis and other diseases like intracranial stenosis, dural fistula. The market is primarily driven by the increase in incidence and prevalence of neurovascular diseases like intracranial aneurysm, stroke and arteriovenous malformations, increase in the aging population, technological advancement, a ....

United States , Deutschland Verwaltungs Gmb , Laura Wood , Cerus Endovascular , Johnson Cerenovus , Medtronic Public Limited Company , Kaneka Pharma America , Ceretrieve Ltd Israel , Artio Medical Inc , Porters Five Force Analysis , Stryker Corporation , Therapeutics Inc , Monarch Biosciences Inc , Cerevasc Inc , Cardinal Health Inc , Office Hours Call , Regulatory Affairs , Research Methodology , Natec Medical Ltd , Jiushi Shenkang Medical Technology China , Sequent Medical Inc , Instylla Inc , Boston Scientific Corporation , Wl Gore Associates , Shape Memory Medical Inc , Microport Scientific Corporation ,

Cerus Endovascular Receives FDA Breakthrough Device Designation for its Contour Neurovascular System™

Cerus Endovascular Receives FDA Breakthrough Device Designation for its Contour Neurovascular System™
News provided by
Share this article
Share this article
FREMONT, Calif. and OXFORD, United Kingdom, Feb. 11, 2021 /PRNewswire/ Cerus Endovascular Ltd., a privately-held, commercial-stage medical device company, today announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its Contour Neurovascular System™.
Breakthrough Device Designation is granted to medical devices and device-led combination products that provide the potential for a more effective treatment option for life-threatening or irreversibly debilitating diseases. The designation expedites the traditional development, assessment and review process, and enables medical professionals to get access to new developments quickly. ....

United Kingdom , Sam Milstein , Stephen Griffin , Lori Adels , Cerus Endovascular , Prnewswire Cerus Endovascular Ltd , Cerus Endovascular Ltd , Drug Administration , Rx Communications Group , Endovascular Ltd , Breakthrough Device Designation , Contour Neurovascular System , Device Designation , Chief Compliance Officer , Investigational Device Exemption , Ceru Chairman , Contour System , Neqstent Coil Assisted Flow Diverter , Communications Group , ஒன்றுபட்டது கிஂக்டம் , சாம் மில்ஸ்டீன் , ஸ்டீபன் கிரிஃபின் , ர்க்ஸ் தகவல்தொடர்புகள் குழு , எண்டோவாஸ்குலர் லிமிடெட் , திருப்புமுனை சாதனம் பதவி , சாதனம் பதவி ,